IRADIMED (IRMD) CEO trust sells 7,500 shares under 10b5-1 plan

Rhea-AI Filing Summary

IRADIMED CORP’s CEO, president and chairman Roger E. Susi reported indirect open‑market sales of company common stock by the Phillip Susi 2008 Dynasty Trust. The trust sold 5,000 shares on March 9, 2026 at a weighted average price of $100.04 per share and 2,500 shares on March 10, 2026 at a weighted average price of $100.11 per share. These sales were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 5, 2025. Following the March 10 sale, the dynasty trust held 2,247,500 shares indirectly, and additional indirect holdings are reported for the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.

Insights

Insider transactions analyst

Small CEO‑linked trust sales under a 10b5‑1 plan look routine.

The filing shows the Phillip Susi 2008 Dynasty Trust sold 7,500 IRADIMED CORP common shares in two open‑market trades around $100 per share. After these sales, the trust still holds 2,247,500 shares, indicating only a modest reduction in this position.

The trades were executed pursuant to a pre‑established Rule 10b5‑1 trading plan adopted on November 5, 2025, suggesting they were scheduled in advance rather than timed opportunistically. The reporting person also disclaims full beneficial ownership, limiting the economic signal for investors.

Because the sale volume is small relative to the remaining reported indirect holdings and occurs under a trading plan, this activity typically reads as routine portfolio management rather than a major change in insider sentiment. Subsequent insider reports may further clarify any ongoing selling pattern.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PRESIDENT, CHAIRMAN

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		S(1)		5,000	D	$100.04(2)	2,250,000	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	03/10/2026		S(1)		2,500	D	$100.11(3)	2,247,500	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500(4)	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.

2. This transaction was executed in multiple trades at prices ranging from $100.00 to $100.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $100.00 to $100.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Roger E. Susi	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IRADIMED CORP (IRMD) report for Roger E. Susi?

IRADIMED CORP reported that the Phillip Susi 2008 Dynasty Trust, associated with CEO Roger E. Susi, sold 7,500 common shares in open‑market transactions. The trades occurred on March 9 and March 10, 2026, at weighted average prices around $100 per share.

At what prices were the IRADIMED (IRMD) insider sales executed?

The trust sold 5,000 IRADIMED shares at a weighted average price of $100.04 on March 9, 2026, and 2,500 shares at a weighted average price of $100.11 on March 10, 2026. Both entries note execution across multiple trades within narrow price ranges.

How many IRADIMED (IRMD) shares does the CEO-linked dynasty trust hold after the sale?

After the March 10, 2026 sale, the Phillip Susi 2008 Dynasty Trust is reported to hold 2,247,500 IRADIMED common shares indirectly. Additional indirect holdings are listed for the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust in the same Form 4 filing.

Were the recent IRADIMED (IRMD) insider sales made under a Rule 10b5-1 plan?

Yes. The Form 4 states the reported sales were effected pursuant to a Rule 10b5‑1 trading plan adopted by the reporting person on November 5, 2025. Such plans pre‑schedule trades, often making their timing less informative about short‑term insider views.

Does Roger E. Susi claim full beneficial ownership of the IRADIMED (IRMD) shares reported?

No. A footnote explains the reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest. This means some shares are held by related trusts, and he does not assert full economic ownership of every reported share.

What types of ownership are shown in the IRADIMED (IRMD) Form 4 for Roger E. Susi?

All reported positions are indirect holdings, including shares held by the Phillip Susi 2008 Dynasty Trust, the Roger E. Susi Revocable Trust, and the Matthew Susi 2008 Dynasty Trust. The nature-of-ownership descriptions specify each trust as the holding entity, not direct personal ownership.